NICE says no to Celgene's Vidaza for leukaemia
This article was originally published in Scrip
Executive Summary
Celgene's Vidaza (azacitidine) would not be a cost-effective use of NHS resources treating myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia and acute myeloid leukaemia, says NICE, the health technology appraisal body for England and Wales.